Morgan Stanley Maintains Overweight on Celldex Therapeutics, Raises Price Target to $57

Morgan Stanley analyst Judah Frommer has maintained an Overweight rating on Celldex Therapeutics (NASDAQ: CLDX) and increased the price target from $50 to $57. This adjustment reflects a positive outlook for the company's performance in the market.